Related by context. All words. (Click for frequent words.) 71 ALT elevation 69 log# copies mL 68 CR nPR 68 PREZISTA r arm 68 NNT = 67 PASI scores 67 isoprostane 67 mL/min/#.# m 2 67 Forced Expiratory Volume 67 Index CDAI 67 lumbar spine BMD 66 -#.# log# 66 -#.# log# copies mL 66 REYATAZ r arm 66 serum aminotransferase levels 66 % Confidence Interval 66 moderate renal impairment 66 serum creatinine levels 66 Peginterferon Alfa 2a 65 oxycodone CR 65 nondiabetic patients 65 echocardiographic parameters 65 pmol L 65 -#.# mg dL [002] 65 relapsed MM 65 baseline FEV1 65 mg TID 65 PSA nadir 65 morphometric vertebral fractures 65 QTcF 65 elevated LDH 65 creatinine ratio 65 baseline HbA1c 65 Fasting blood glucose 65 rs# [004] 65 Hb A1C 65 infliximab monotherapy 65 CrCl 65 preoperative PSA 65 baseline serum creatinine 65 spirometric 65 mg BID dose 64 μmol L 64 MMSE score 64 adjunctive placebo 64 Non inferiority 64 HBeAg negative patients 64 del 5q MDS 64 biologic DMARD 64 antibody titer 64 PSADT 64 DAS# remission 64 Castration Resistant Prostate Cancer 64 #.#mg/dL 64 unfractionated heparin UFH 64 underwent resection 64 HBeAg seroconversion 64 aminotransferases 64 EDSS score 64 serum cortisol 64 mU liter 64 bortezomib refractory 64 NMIBC 64 Capacity FVC 64 biochemical relapse 64 glycated hemoglobin levels 64 serum phosphorous 64 mcg BID 64 pg mL 64 generalized edema 64 microgram kg 63 % CI #.#-#.# [004] 63 MADRS score 63 lopinavir r arm 63 follicular lymphomas 63 NPH insulin 63 complete cytogenetic response 63 Infusion Reactions Severe 63 anemia hemoglobin 63 atorvastatin #mg 63 hematological parameters 63 lipoprotein Lp 63 ACR# responses 63 HOMA IR 63 ng dL 63 Mg Uk 63 #mg BID [003] 63 intact parathyroid hormone 63 specific antigen PSA 63 Crohn Disease Activity 63 #.#/#.# mm Hg [003] 63 CDAI score 63 SGRQ 63 aspartate aminotransferase AST 63 #OHD 63 HbA 1c levels 63 fluticasone salmeterol 63 HER2 expression 63 Oral Fingolimod 63 pg ml 63 coronary stenosis 63 anaphylactic reactions bronchospasm 63 advanced adenomas 63 μg L 63 albumin excretion rate 63 mg/# h 63 CI #.#-#.# [001] 63 ANCOVA 63 serum magnesium 63 ertapenem 63 confidence intervals CIs 63 hours postdose 63 achieved CCyR 63 Operative mortality 63 alanine aminotransferase 63 EDSS scores 63 PaO 2 63 lactate dehydrogenase LDH 63 R# #mg BID 63 SGPT 63 poor metabolizers 63 Cholinesterase Inhibitors 63 pT3 62 Folfox 62 macroalbuminuria 62 lymphocytosis 62 virological response 62 prednisone prednisolone plus 62 apo B apo AI 62 Hormone Refractory Prostate Cancer 62 multivariable adjusted 62 multivariable analysis 62 adjunctive ABILIFY 62 β blockers 62 Gastrointestinal Stromal Tumors 62 ‰ ¥ 62 Ejection Fraction 62 certolizumab 62 IU ml 62 LV dysfunction 62 Hazard Ratio HR 62 aminotransferase levels 62 0 document.write sline 62 aspartate aminotransferase 62 atherogenic dyslipidemia 62 BENICAR HCT 62 estimated GFR 62 mL sec 62 neutrophil counts 62 Median PFS 62 salmeterol fluticasone 62 hip BMD 62 Scale EDSS 62 beta carotene supplementation 62 5-FU/LV 62 abacavir lamivudine 62 TIMP 1 62 ATV RTV 62 Pharmacokinetic parameters 62 hemoglobin A1c HbA1c 62 F FLT 62 K ras mutations 62 logistic regression model 62 urine albumin 62 6MWD 62 Thal Dex 62 ASCUS 62 adriamycin 62 deoxy 62 #mg q8h 62 biochemical recurrence 62 genotypic resistance 62 reduce serum phosphate 62 CYT# potent vascular disrupting 62 Flu Cy 62 ug dose 62 FEV ^ sub 62 mild renal insufficiency 62 Rating Scale MADRS 62 somatostatin analog 62 recurrent venous thromboembolism 62 CIN2 + 62 HBeAg 62 glomerular filtration rate 62 Hamilton Anxiety Scale 62 mIU ml 62 T2 lesions 62 apolipoprotein B 62 CCyR 62 adenoma recurrence 62 budesonide pMDI 62 nonfasting triglyceride levels 62 μg d 62 tertiles 62 Demonstrated Significant 61 HAQ DI 61 sUA 61 nmol liter 61 % CI #.#-#.# [007] 61 HbA1C levels 61 thrombosis embolism 61 advanced adenoma 61 % CI #.#-#.# [006] 61 -#.# mg dL [001] 61 μg dose 61 glycosylated hemoglobin HbA1c 61 % CI #.#-#.# [003] 61 undetectable HBV DNA 61 Kaplan Meier analysis 61 #.# Kenyan Shilling 61 clinically meaningful improvement 61 interleukin IL -6 61 mg Proellex 61 alanine aminotransferase ALT 61 FDG uptake 61 Patients Receiving 61 Febrile neutropenia 61 quetiapine XR 61 0 document.write 61 arterial oxygen saturation 61 HBeAg + 61 HIV HCV coinfected 61 fluorodeoxyglucose positron emission tomography 61 CIMZIA ™ 61 ug kg 61 histological subtype 61 Prostate Cancer Recurrence 61 underwent surgical resection 61 CYP#A# CYP#D# 61 serum concentrations 61 J Natl Cancer Inst 61 -#.# ± [002] 61 Arch Intern Med 61 ALT elevations 61 prospectively stratified 61 colesevelam HCl 61 TEAEs 61 proton MR spectroscopy 61 Hyperlipidemia 61 refractory NSCLC 61 FOSRENOL ® 61 Mg Usa 61 Plasma concentrations 61 virologic responses 61 univariate analyzes 61 Tumor shrinkage 61 multivariable Cox 61 log# reduction 61 FEV1 Forced Expiratory Volume 61 serum HBV DNA 61 detectable HCV RNA 61 locoregional recurrence 61 postoperative chemotherapy 61 postintervention 61 BARACLUDE ® 61 stage IIIb IV 61 mcg QD 61 lowest tertile 61 linaclotide treated 61 triiodothyronine 61 Hypotension 61 ADAS cog 61 tipranavir r 61 Expanded Disability Status 61 androgen suppression 61 neuropathy sensory 61 Adjuvant Treatment 61 #mg dose [002] 61 confidence interval #.#-#.# 61 Montgomery Asberg Depression 61 pimecrolimus cream 61 mmol l 61 TLUS 61 INVEGA ® 61 Relapsing Remitting Multiple Sclerosis 61 oral hypoglycemic agent 61 lispro 61 logistic regression analysis 61 response CCyR 61 pCR 61 atheroma volume 61 virologic breakthrough 61 prospectively defined 61 Main Outcome Measures 61 piotr.skolimowski @ thomson.com 61 timepoints 61 glucuronide 61 univariate analysis 61 tertile 61 dose atorvastatin 61 deep venous thromboses 61 achieved ACR# 61 mcg albinterferon alfa 2b 61 microg 61 placebo fluoxetine 61 hepatic enzymes 61 adiponectin concentrations 61 Double Blind Randomized 61 baseline LDH 61 HbA 1c 60 CK # plasma concentrations 60 specific alkaline phosphatase 60 APTIVUS r 60 APACHE II 60 Subgroup analysis 60 ALT flares 60 Relapsing Multiple Sclerosis 60 CLL SLL 60 Cardiorespiratory fitness 60 angiographic outcomes 60 Eur J Cancer 60 rizatriptan 60 ml min 60 WEEK ENDING INDEX 60 oxycodone IR 60 SUVmax 60 PLX STROKE targeting 60 multivariate analyzes 60 stomatitis pharyngitis 60 CI -#.# 60 â ‰ ¥ 60 cells uL 60 repeat paracentesis 60 myocardial viability 60 Alzheimer Disease Assessment 60 Retreatment 60 MIC# [001] 60 serum IGF 60 stage IIIB 60 perioperative mortality 60 Main Outcome Measure 60 preintervention 60 elevated serum creatinine 60 hemoglobin A1c levels 60 recurrent VTE 60 pyrexia mucositis sepsis febrile 60 PRADAXA #mg 60 FOLPI 60 myocardial infarction ventricular fibrillation 60 bezafibrate 60 p# antigen 60 OS = ISD/#/#/# 60 gemcitabine cisplatin 60 comparator arm 60 interquartile range 60 % CI #.#-#.# [008] 60 #Gy 60 pulmonary exacerbations 60 tipranavir ritonavir 60 femoral neck BMD 60 suppl. 60 hsCRP levels 60 % #gt 60 Nephrol Dial Transplant 60 Newly Diagnosed Multiple Myeloma 60 pretest probability 60 Relapsed Refractory Multiple Myeloma 60 serum prostate 60 Kaplan Meier estimates 60 CR CRu 60 Cystatin C 60 serum triglycerides 60 mean ± SEM 60 HAM D# scores 60 sustained virological response 60 SGOT 60 posttreatment 60 Cardiotoxicity 60 Non Responders 60 evaluable subjects 60 nmol l 60 uM 60 transaminase levels 60 thyrotropin levels 60 #.#-#.# [011] 60 cerebrovascular events 60 HCV SPRINT 60 haematologic 60 cTnT levels 60 Supplementary Table 60 serum HCV RNA 60 dapagliflozin plus 60 piperacillin tazobactam 60 mRNA expression 60 diastolic blood pressures 60 CLA supplementation 60 Skin sterol 60 leukocyte counts 60 calculated creatinine clearance 60 lymphocyte count 60 Am J Cardiol 60 hemoglobin Hb 60 eplerenone 60 p = NS 60 Psychiatry Clin Neurosci 60 Metastatic Renal Cell Carcinoma 60 mg XP# 60 KRAS mutations occur 60 variance ANOVA 60 mL/min/#.# m2 60 μg liter 60 CIN3 60 Plus Ribavirin 60 highest tertile 60 HPV-#/# 60 IGFBP 60 bioavailable testosterone 60 Obes Res 60 FFNS 60 J Antimicrob Chemother 60 binary restenosis 60 serum phosphate 60 mg qd 60 progression TTP 60 ß blockers 60 symptomatic VTE 60 mL kg 60 Brief Psychiatric 60 liver histology 60 endoscopic remission 60 Kaplan Meier 60 T1c 60 serum leptin 60 virologic failure 60 Voter Abstentions 60 p = .# [002] 60 urinary N telopeptide 60 HBeAg positive patients 60 serum testosterone 60 exhaled NO 60 ritonavir boosted 60 tirofiban 60 micafungin 60 Chronic HCV 60 glycated hemoglobin HbA1c 60 treat NNT 60 Comorbidities 60 lipid lowering agents 60 abnormal p# biomarker 60 Meets Primary Endpoint 60 Baseline characteristics 60 FOLFOX4 60 IOP lowering 60 DAS# CRP 60 nmol L 60 Arch Neurol 60 8mg/kg 60 inhibin B 60 overt nephropathy 60 TP# mutations 60 Arterial stiffness 60 KRAS mutations 60 ± SEM 60 rFSH 60 System IPSS 60 hemodynamically significant 60 XIENCE V PROMUS Stent 60 Forced Vital 60 CYP#A# substrate 60 Unit Handling Equipment 60 See CLINICAL PHARMACOLOGY 60 fasting plasma glucose FPG 60 NIHSS 59 prespecified secondary 59 J Am Soc 59 benazepril 59 oral antidiabetic medication 59 liver enzymes ALT 59 HER2 positivity 59 receiving INTRON 59 PegIFN RBV 59 mEq L 59 Pemetrexed 59 tapentadol ER 59 pretreatment serum 59 AST ALT 59 ziprasidone 59 glulisine 59 T2 lesion volume 59 Secondary efficacy endpoints 59 ug ml 59 Cmax 59 Nebulized 59 QTc prolongation 59 lispro alone 59 heterozygotes 59 Index CDAI score 59 leukocyte count 59 SCr 59 odds ratios ORs 59 mg q#h 59 nonfatal MI 59 IFN α 59 #.#ng/ml 59 p = #.# [003] 59 urinary calcium 59 doxazosin 59 Randomized Phase 59 estimated glomerular filtration 59 dopamine partial agonist 59 Proteinuria 59 FOLFOX6 59 ARB telmisartan 59 titrated glipizide 59 complement inhibitor eculizumab 59 Clinical Outcome 59 ECOG PS 59 Month Avg 59 zoledronate 59 ADCS CGIC 59 lactate dehydrogenase 59 Antitumor Activity 59 Persistent Sleep 59 Tumor Response 59 hypophosphatemia 59 PEG IFN 59 monocyte chemoattractant protein 59 albumin creatinine ratio 59 Eur J Endocrinol 59 oral allopurinol 59 4mg/kg 59 F FDG PET 59 BRAF V#E 59 NIHSS score 59 Renal Insufficiency 59 K#N 59 multivariate Cox 59 low dose cytarabine 59 mcg mL 59 CIMZIA TM 59 Bone Metastases 59 serum phosphate levels 59 Naive Patients 59 heFH 59 VKORC1 59 cTnI 59 TIMP 59 daunorubicin 59 racemic albuterol 59 serum phosphorus 59 PROSTVAC VF 59 plasma kallikrein inhibitor 59 plasma HCV RNA 59 #μg [001] 59 bronchoalveolar lavage fluid 59 tolterodine ER 59 S. aureus isolates 59 serum estradiol 59 Natalizumab 59 gadolinium enhancing lesions 59 Ann Oncol 59 PREZISTA ritonavir 59 Scale EDSS score 59 postmenopausal osteoporotic women 59 eosinophil count 59 TRAIL R1 59 interleukin IL 59 μg dL 59 http:/events.fai.org 59 advanced hepatocellular carcinoma 59 jana.mlcochova @ thomson.com 59 ml kg 59 Acetate Rectal Suppositories 59 Univariate analysis 59 Doxil ® 59 chemoradiation therapy 59 serum homocysteine 59 Ann Intern Med 59 Engerix B 59 CD3 + 59 progesterone receptor negative 59 sitosterol 59 Amgen Neulasta R 59 RLAI 59 MoxDuo TM IR 59 Kidney Int 59 RECORD1 59 #mg/day [001] 59 OGTT 59 TURBT 59 androgen deprivation 59 FUSILEV enhances 59 #-# Full Text 59 QIDS SR 59 carotid intima media 59 serum CRP 59 activated partial thromboplastin 59 statistical significance p 59 highly emetogenic 59 LEXIVA r 59 metaplasia 59 intima media thickness 59 Posaconazole 59 receiving XGEVA 59 nondiabetic subjects 59 Postoperative complications 59 NNRTI resistance 59 adefovir treated 59 SSRI SNRI 59 goserelin 59 salmeterol fluticasone propionate 59 aldosterone antagonist 59 aminotransferase ALT 59 serum uric acid 59 virologic response 59 estramustine 59 Serious adverse reactions 59 mg eq 59 univariate 59 troponin T 59 genotype 1a 59 HPA axis suppression 59 Partial Responses 59 Å -1 59 cell adhesion molecule 59 metabolite concentrations 59 HGPIN 59 phosphorylated tau 59 receiving VICTRELIS 59 WOMAC pain 59 del 5q 59 abdominal adiposity 59 TWYNSTA 59 Demonstrate Significant 59 nonsignificant difference 59 COZAAR 59 naïve HCV 59 REMICADE monotherapy 59 % CI #.#-#.# [001] 59 Localized Prostate Cancer 59 azilsartan medoxomil 59 metastatic GIST 59 diabetes mellitus DM 59 definite stent thrombosis 59 Insulin Glargine 59 #mg BID [001] 59 Suppl. 59 Arch Dermatol 59 EGFR HER2 59 non valvular atrial 59 AUC0 59 + PH# 59 elevated triglyceride levels 59 fructosamine 59 KRAS status 59 mild renal impairment 59 Montgomery Åsberg Depression 59 pegylated liposomal doxorubicin 59 severe exacerbations 59 TOP2A 59 secondary efficacy endpoint 59 Leukemias 59 weekly CSBMs 59 Kinoid 59 Neurol 59 NYHA functional class 59 mg ustekinumab 59 Soft Tissue Sarcoma 59 LV ejection fraction 59 x ULN 59 Psoriasis Area 59 serum potassium 59 cEVR 59 -5 -6 59 Initiated Phase 59 colorectal adenoma 59 IBDQ 59 piotr.skolimowski @ thomsonreuters.com 59 postoperative mortality 59 pharmacodynamic parameters 59 thromboembolic complications 59 impaired glucose metabolism 59 umol L 59 J Am Coll 59 paricalcitol 59 μg kg 59 MGd 59 fasting triglyceride levels 59 5 Fluorouracil 59 Levels Linked 59 affective psychosis 59 platelet reactivity 59 Statistically Significant 59 anti JCV antibodies 59 HCV genotype 59 mammographic density 59 CIN3 + 59 MCyR 59 Fracture Risk 59 serum urate 59 mediated dilation 59 nucleoside naive 59 β blocker 59 Ann Rheum Dis 59 Hazard Ratio 59 % CI #.#-#.# [005] 58 Visual Analogue Scale VAS 58 HYZAAR 58 Tasigna prolongs 58 dexamethasone Decadron 58 Cardiopulmonary bypass 58 ACR# response 58 RUSSIA SWAP 58 Noncritical violations found 58 mg kg dose 58 urinary oxalate 58 titrated glipizide plus 58 annualized relapse 58 glycated hemoglobin 58 eGFR 58 IFN beta 58 STRIDE PD 58 Supplemental Figure 58 resected pancreatic cancer 58 μmol l 58 nmol 58 conditional logistic regression 58 comorbid conditions 58 normal ULN 58 corticosteroid dose 58 venlafaxine XR 58 Squamous 58 mmol L 58 Eur Urol 58 seropositivity 58 μg ml 58 urinary albumin 58 invasive carcinomas 58 hematologic toxicity 58 treatment naive genotype 58 aged ≥ 58 nanomolar 58 Secondary endpoints 58 microalbuminuria 58 ACTEMRA TM 58 saline placebo 58 gadolinium enhancing 58 Apolipoprotein B 58 histologic subtype 58 DLTs 58 Viread Emtriva Sustiva 58 Score TOS 58 Viral load 58 inhaled budesonide 58 stratifying patients 58 per deciliter mg 58 NovoSeven ® 58 lipid lowering medications 58 5alpha reductase 58 mcg linaclotide 58 plus OBT 58 mg/# hours 58 cytopenias 58 moderate hepatic insufficiency 58 medically inoperable 58 THE COSMOS ROCKS 58 mm Hg diastolic 58 clodronate 58 receiving ISENTRESS 58 overt hypothyroidism 58 #mmHg [001] 58 treatment naïve genotype 58 galiximab 58 caspofungin 58 Follicular Lymphoma 58 Rate ORR 58 Prognostic Value 58 TNF blocker therapy 58 variant angina 58 Complete Remission 58 Eur Respir J 58 laboratory abnormalities 58 Psychiatry Res 58 folinic acid 58 receptor kinase 58 pT2 58 Treated Patients 58 hematopoietic cancers 58 angiotensin converting enzyme inhibitors 58 pmol liter 58 Serum concentrations 58 irinotecan cisplatin 58 NATRECOR ® 58 IPAH 58 desvenlafaxine succinate 58 Warfarin Coumadin 58 abacavir Ziagen 58 elevated transaminases 58 ischemic lesions 58 Sustained Virological Response 58 receiving golimumab 58 Platelet counts 58 5 hydroxytryptamine 58 serum lipid levels 58 ADHD RS 58 Basal Cell 58 BYSTOLIC 58 FluCAM arm 58 Pooled Analysis 58 blood Phe 58 inflammatory biomarkers 58 lymph node metastasis 58 non splenectomized 58 BRAF gene mutations 58 IC# = 58 osteopenic 58 receiving PEGINTRON 58 nonvertebral fractures 58 CK MB 58 mycophenolate mofetil 58 severe renal impairment 58 Adenomas 58 multivariate logistic regression 58 recurrent glioblastoma multiforme 58 Left Ventricular Ejection Fraction 58 liver transplant recipients 58 6mg 58 fraction LVEF 58 completely resected 58 Elitek 58 ug mL 58 TNFalpha 58 Randomized Study 58 CANCIDAS 58 -#.# mmHg 58 hypercalciuria 58 indinavir 58 KRAS wild 58 leukocytosis 58 Univariate 58 extracapsular extension 58 left ventricular diastolic 58 DAS# scores 58 Int Clin Psychopharmacol 58 Zovirax acyclovir 58 Adjuvant Chemotherapy 58 J Allergy Clin 58 IPSS 58 hepatorenal syndrome 58 NIH CPSI 58 shorter telomere length 58 Prehypertension 58 nadroparin 58 elevated ALT 58 Papillary 58 intima media thickness IMT 58 Diabetic Foot Ulcer 58 insulin detemir 58 hepatocellular carcinomas 58 sleeve lobectomy 58 candesartan cilexetil 58 HIV uninfected 58 GnRH agonist 58 thromboembolic 58 placebo PBO 58 intramuscular dose 58 Severity Index PASI 58 subtrochanteric 58 p# biomarker 58 plasma folate 58 oral diclofenac 58 serum urate levels 58 -#.# mmol L 58 Adefovir 58 ADAS Cog 58 TIE DOWN ROPING 58 suppl #S #S 58 seroprotection 58 Unified Parkinson Disease 58 tHcy 58 Free Full Text 58 MetS 58 Apidra ® 58 bronchial hyperresponsiveness 58 CD4 ^ sup 58 #ng/ml 58 ACR Pedi 58 congenital toxoplasmosis 58 metabolic parameters 58 alteplase 58 tumor histology 58 leukopenia 58 ischemia driven 58 Adjuvant chemotherapy 58 #.#/#.# mmHg [001] 58 HBeAg negative chronic hepatitis 58 Somnolence 58 Hypomagnesemia occurred 58 g dl 58 endometrial thickness 58 TAXUS p value 58 Disord 58 divalproex sodium 58 antipsychotic efficacy 58 artery stenosis 58 pamidronate 58 MAGE A3 ASCI 58 CHANGE WEEKLY CHANGE 58 CRp 58 HIV RNA 58 serum ALT 58 Pearson correlation coefficient 58 cytoreductive nephrectomy 58 Relapsed Refractory 58 ACR# ACR# 58 collagenous colitis 58 ACE Inhibitors 58 NSABP B 58 hour bronchodilation 58 cystatin 58 patients receiving myelosuppressive 58 CC genotype 58 tumor necrosis 58 EpCAM expression 58 extrapyramidal symptoms 58 #.#mmol L [002] 58 Hemodialysis Patients 58 Severity MSCS score 58 ovarian carcinoma 58 bladder carcinoma 58 baseline Hb 58 Erythropoietic therapies may 58 Patency 58 TNF alpha IL 58 See WARNINGS 58 Hypertrophy 58 triglyceride TG 58 HbA 1C 58 biliary tract cancer 58 trough FEV1 58 CDAI 58 biopsy Gleason 58 dacarbazine 58 h g 58 mCi kg 58 tHcy concentrations 58 matrix metalloproteinase MMP 58 BUPHENYL R sodium phenylbutyrate 58 isoenzyme 58 allele frequencies 58 arterial thromboembolic events 58 postdose 58 creatinine clearance 58 methotrexate monotherapy 58 CD# + [001] 58 Hepatitis C Genotype 58 SVR# 58 Interferon gamma 58 deCODE AF TM 58 plasminogen activator inhibitor 58 amoxicillin clavulanate 58 ABC/3TC 58 noninferior 58 myocardial infarctions MIs 58 Atypical Hemolytic Uremic Syndrome 58 HDRS 58 cyclooxygenase COX 58 underwent CABG 58 FOLFIRI 58 diabetes dyslipidemia 58 revascularizations 58 HbA1c levels 58 systemic corticosteroid 58 IIIa inhibitor 58 Islands Sportfishing 58 lumbar spine bone 58 HBsAg 58 glomerular filtration 58 dosing cohorts 58 apolipoprotein E4 58 STELARA ® 58 EBMT criteria 58 telaprevir dosed 58 Insulin sensitivity 58 adrian.krajewski @ thomson.com 58 ord = + krdDartOrd 58 pawel.sobczak @ thomson.com 58 anagrelide 58 tapentadol IR 57 CagA 57 ximelagatran 57 lamivudine monotherapy 57 tsp vanilla extract 57 fasting plasma glucose 57 node metastases 57 ß = 57 oral levofloxacin 57 Consensus +#.# 57 Beta Amyloid 57 ps :# 57 nonobese 57 IELT 57 Decitabine 57 #.#/journal.pmed.# 57 BRCA2 mutation carriers 57 #mg/m# [001] 57 #mg #mg #mg [003] 57 CsA 57 UPDRS motor